Longtime Outcome After Intraosseous Application of Autologous Mesenchymal Stromal Cells in Pediatric Patients and Young Adults with Avascular Necrosis After Steroid or Chemotherapy
- 1 July 2020
- journal article
- research article
- Published by Mary Ann Liebert Inc in Stem Cells and Development
- Vol. 29 (13), 811-822
- https://doi.org/10.1089/scd.2020.0019
Abstract
Avascular necrosis (AVN) is a severe complication of immunosuppressant therapy or chemotherapy. A beneficial AVN therapy with core decompression (CD) and intraosseous infusion of mesenchymal stromal cells (MSC) has been described in adult patients, but there are only few data on MSC applications in pediatric and young adult patients (PYAP). Between 2006 and 2015, 14 AVN lesions of 10 PYAP (6 females) with a median age of 16.9 years (range 8.5 – 25.8 years) received CD and intraosseous application of autologous MSC. Data of these patients were analyzed regarding efficacy, safety and feasibility of this procedure as AVN therapy and compared to a control group of 13 AVN lesions of 11 PYAP (5 females) with a median age of 17.9 years (range 13.5 – 27.5 years) who received CD only. During the follow-up analysis (MSC group: median 3.1 (1.6 - 5.8) years after CD; CD group: median 2.0 (1.5 - 8.5) years after CD), relative lesion sizes (as assessed by MRI) compared to the initial lesion volume, were significantly lower (p<0.05) in the MSC group (volume reduction to a median of 18.5%) when compared to the CD group (58.0%). One lesion in the MSC group comprised a complete remission. Size progression was not observed in either group. Clinical improvement (pain, mobility) was not significantly different between the two groups. None of the patients experienced treatment-related adverse effects. CD and additional MSC application was regarded safe, effective, feasible and superior in reducing the lesion size when compared to CD only. Prospective, randomized clinical trials are needed to further evaluate these findings.Keywords
This publication has 51 references indexed in Scilit:
- Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case seriesJournal of Medical Case Reports, 2011
- Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatologyJournal of Cellular and Molecular Medicine, 2011
- Micro‐CT‐based bone ceramic scaffolding and its performance after seeding with mesenchymal stem cells for repair of load‐bearing bone defect in canine femoral headJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2011
- Application of human umbilical cord blood-derived mesenchymal stem cells in disease modelsWorld Journal of Stem Cells, 2010
- Treatment Outcomes of Triplane and Tillaux Fractures of the Ankle in AdolescenceClinics in Orthopedic Surgery, 2010
- A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology GroupBlood, 2008
- Use of a syringe as a drill sleeve for core decompression of the femoral head in osteonecrosisActa Orthopaedica, 2007
- The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of boneThe Journal of Bone and Joint Surgery. British volume, 2005
- Joint Preserving Surgery for Osteonecrosis and Osteochondral Defects after Chemotherapy in ChildhoodKlinische Padiatrie, 2003
- Bone regeneration by implantation of purified, culture‐expanded human mesenchymal stem cellsJournal of Orthopaedic Research, 1998